Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Nationales Krebsinstitut "Cancer Moonshot Biobank"

11. November 2026 aktualisiert von: National Cancer Institute (NCI)

Cancer Moonshot Biobank-Forschungsprotokoll

This trial collects multiple tissue and blood samples, along with medical information, from cancer patients. The "Cancer Moonshot Biobank" is a longitudinal study. This means it collects and stores samples and information over time, throughout the course of a patient's cancer treatment. By looking at samples and information collected from the same people over time, researchers hope to better understand how cancer changes over time and over the course of medical treatments.

Studienübersicht

Status

Aktiv, nicht rekrutierend

Intervention / Behandlung

Detaillierte Beschreibung

PRIMARY OBJECTIVE:

I. To support current and future investigations into drug resistance and sensitivity and other National Cancer Institute (NCI)-sponsored cancer research initiatives through the procurement and distribution of multiple longitudinal biospecimens and associated data from a diverse group of cancer patients who are undergoing standard of care treatment at NCI Community Oncology Research Program (NCORP) sites and other National Clinical Trials Network (NCTN) sites.

SECONDARY OBJECTIVES:

I. To provide a service of value to study participants and their medical providers through the performance of molecular profiling assays on tumor samples in a Clinical Laboratory Improvement Act (CLIA)-certified laboratory and reporting of results to physicians and patients that they may opt to use in clinical management, including analysis of data for acquired resistance mechanisms.

II. To enable the development of patient-derived models such as cell lines and xenografts for cancer researchers through the provision of biospecimens from up to 20% of study participants to the NCI's Patient Derived Models Repository (PDMR), a national resource available to investigators.

III. To develop and implement robust approaches in patient and provider engagement to improve understanding of biobanking and its relationship to cancer research and increase representation of minority and underserved study participants in cancer research.

IV. To develop increased capabilities in United States (U.S.) community hospitals and clinics for contribution to cancer research through biobanking activities.

V. To enable secondary research generated from the project through deposition of data in public repositories such as Cancer Research Data Commons (CRDC), The Cancer Imaging Archive (TCIA) and database of Genotypes and Phenotypes (dbGaP) and other potential NCI databases, including clinical, radiology and pathology data with an emphasis on treatment response and outcome data.

VI. To provide residual biospecimens and associated data from the project to the cancer research community.

OUTLINE:

Patients undergo collection of tissue samples during baseline and at time of disease progression and collection of blood samples throughout the study, including at time of disease progression. Patients with hematological malignancies also undergo collection of bone marrow and cerebral spinal fluid at the same time points. Archival blood and tissue, as well as bone marrow of patients with hematological malignancies, is also collected if available. Additionally, patients may undergo computed tomography (CT), positron emission tomography (PET)/CT and/or magnetic resonance imaging (MRI) throughout the study, and may undergo paracentesis on study. Patient medical records are reviewed, and data is collected for at least 5 years.

Studientyp

Beobachtungs

Einschreibung (Geschätzt)

1600

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

      • San Juan, Puerto Rico, 00917
        • San Juan Community Oncology Group
      • San Juan, Puerto Rico, 00927
        • Centro Comprensivo de Cancer de UPR
      • San Juan, Puerto Rico, 00936
        • San Juan City Hospital
    • Alabama
      • Daphne, Alabama, Vereinigte Staaten, 36526
        • Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis
      • Fairhope, Alabama, Vereinigte Staaten, 36532
        • Thomas Hospital
      • Mobile, Alabama, Vereinigte Staaten, 36607
        • Mobile Infirmary Medical Center
      • Saraland, Alabama, Vereinigte Staaten, 36571
        • Gulf Health Hospitals Inc/Infirmary Cancer Care - Saraland
    • Arizona
      • Kingman, Arizona, Vereinigte Staaten, 86401
        • Kingman Regional Medical Center
    • Arkansas
      • Fort Smith, Arkansas, Vereinigte Staaten, 72903
        • Mercy Hospital Fort Smith
    • California
      • Arroyo Grande, California, Vereinigte Staaten, 93420
        • PCR Oncology
      • Bakersfield, California, Vereinigte Staaten, 93301
        • AIS Cancer Center at San Joaquin Community Hospital
      • Loma Linda, California, Vereinigte Staaten, 92357
        • Veterans Affairs Loma Linda Healthcare System
      • Salinas, California, Vereinigte Staaten, 93901
        • Salinas Valley Memorial
    • Colorado
      • Brighton, Colorado, Vereinigte Staaten, 80601
        • Intermountain Health Platte Valley Hospital
      • Denver, Colorado, Vereinigte Staaten, 80218
        • Saint Joseph Hospital - Cancer Centers of Colorado
      • Golden, Colorado, Vereinigte Staaten, 80401
        • Lutheran Hospital - Cancer Centers of Colorado
      • Grand Junction, Colorado, Vereinigte Staaten, 81501
        • Saint Mary's Hospital and Regional Medical Center
      • Lafayette, Colorado, Vereinigte Staaten, 80026
        • Good Samaritan Hospital - Cancer Centers of Colorado
    • Connecticut
      • Hartford, Connecticut, Vereinigte Staaten, 06102
        • Hartford Hospital
    • Delaware
      • Dover, Delaware, Vereinigte Staaten, 19901
        • Bayhealth Hospital Kent Campus
      • Milford, Delaware, Vereinigte Staaten, 19963
        • Bayhealth Hospital Sussex Campus
    • Florida
      • Boca Raton, Florida, Vereinigte Staaten, 33486
        • Boca Raton Regional Hospital
      • Deerfield Beach, Florida, Vereinigte Staaten, 33064
        • Broward Health North
      • Fort Lauderdale, Florida, Vereinigte Staaten, 33316
        • Broward Health Medical Center
      • Tampa, Florida, Vereinigte Staaten, 33606
        • Tampa General Hospital
    • Georgia
      • Atlanta, Georgia, Vereinigte Staaten, 30342
        • Northside Hospital
      • Savannah, Georgia, Vereinigte Staaten, 31405
        • Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
    • Illinois
      • Bloomington, Illinois, Vereinigte Staaten, 61704
        • Illinois CancerCare-Bloomington
      • Chicago, Illinois, Vereinigte Staaten, 60612
        • John H Stroger Jr Hospital of Cook County
      • Chicago, Illinois, Vereinigte Staaten, 60625
        • Swedish Covenant Hospital
      • Danville, Illinois, Vereinigte Staaten, 61832
        • Carle at The Riverfront
      • Decatur, Illinois, Vereinigte Staaten, 62526
        • Decatur Memorial Hospital
      • Decatur, Illinois, Vereinigte Staaten, 62526
        • Cancer Care Specialists of Illinois - Decatur
      • Evanston, Illinois, Vereinigte Staaten, 60201
        • NorthShore University HealthSystem-Evanston Hospital
      • Galesburg, Illinois, Vereinigte Staaten, 61401
        • Illinois CancerCare-Galesburg
      • Glenview, Illinois, Vereinigte Staaten, 60026
        • NorthShore University HealthSystem-Glenbrook Hospital
      • Highland Park, Illinois, Vereinigte Staaten, 60035
        • NorthShore University HealthSystem-Highland Park Hospital
      • Mattoon, Illinois, Vereinigte Staaten, 61938
        • Carle Physician Group-Mattoon/Charleston
      • Mount Vernon, Illinois, Vereinigte Staaten, 62864
        • SSM Health Good Samaritan
      • Pekin, Illinois, Vereinigte Staaten, 61554
        • Illinois CancerCare-Pekin
      • Peoria, Illinois, Vereinigte Staaten, 61615
        • Illinois CancerCare-Peoria
      • Urbana, Illinois, Vereinigte Staaten, 61801
        • Carle Cancer Center
      • Washington, Illinois, Vereinigte Staaten, 61571
        • Illinois CancerCare - Washington
    • Iowa
      • Ames, Iowa, Vereinigte Staaten, 50010
        • McFarland Clinic - Ames
      • Bettendorf, Iowa, Vereinigte Staaten, 52722
        • University of Iowa Healthcare Cancer Services Quad Cities
      • Cedar Rapids, Iowa, Vereinigte Staaten, 52403
        • Oncology Associates at Mercy Medical Center
      • Cedar Rapids, Iowa, Vereinigte Staaten, 52402
        • Physicians' Clinic of Iowa PC
      • Des Moines, Iowa, Vereinigte Staaten, 50309
        • Iowa Methodist Medical Center
      • Des Moines, Iowa, Vereinigte Staaten, 50309
        • Blank Children's Hospital
      • Des Moines, Iowa, Vereinigte Staaten, 50309
        • UI Health Care Mission Cancer and Blood - Des Moines Clinic
      • Iowa City, Iowa, Vereinigte Staaten, 52242
        • University of Iowa/Holden Comprehensive Cancer Center
    • Louisiana
      • Baton Rouge, Louisiana, Vereinigte Staaten, 70808
        • Our Lady of the Lake Physician Group
      • New Orleans, Louisiana, Vereinigte Staaten, 70118
        • Children's Hospital New Orleans
      • New Orleans, Louisiana, Vereinigte Staaten, 70112
        • University Medical Center New Orleans
      • Shreveport, Louisiana, Vereinigte Staaten, 71103
        • LSU Health Sciences Center at Shreveport
    • Maine
      • Augusta, Maine, Vereinigte Staaten, 04330
        • Harold Alfond Center for Cancer Care
      • Belfast, Maine, Vereinigte Staaten, 04915
        • MaineHealth Waldo Hospital
      • Biddeford, Maine, Vereinigte Staaten, 04005
        • MaineHealth Maine Medical Center - Biddeford
      • Brunswick, Maine, Vereinigte Staaten, 04011
        • MaineHealth Cancer Care and IV Therapy - Brunswick
      • Brunswick, Maine, Vereinigte Staaten, 04011
        • Mid Coast Hospital
      • Damariscotta, Maine, Vereinigte Staaten, 04543
        • MaineHealth LincolnHealth Hospital
      • Farmington, Maine, Vereinigte Staaten, 04938
        • MaineHealth Franklin Hospital
      • Lewiston, Maine, Vereinigte Staaten, 04240
        • Saint Mary's Regional Medical Center
      • Norway, Maine, Vereinigte Staaten, 04268
        • MaineHealth Stephens Hospital
      • Portland, Maine, Vereinigte Staaten, 04102
        • Maine Medical Partners Surgical Care
      • Portland, Maine, Vereinigte Staaten, 04102
        • MMP Surgical Care Casco Bay
      • Portland, Maine, Vereinigte Staaten, 04102
        • MaineHealth Maine Medical Center - Portland
      • Rockport, Maine, Vereinigte Staaten, 04856
        • Penobscot Bay Medical Center
      • Sanford, Maine, Vereinigte Staaten, 04073
        • MaineHealth Cancer Care and IV Therapy - Sanford
      • Scarborough, Maine, Vereinigte Staaten, 04074
        • Maine Children's Cancer Program
      • Scarborough, Maine, Vereinigte Staaten, 04074
        • MaineHealth Maine Medical Center- Scarborough
      • South Portland, Maine, Vereinigte Staaten, 04106
        • MaineHealth Cancer Care and IV Therapy - South Portland
      • South Portland, Maine, Vereinigte Staaten, 04106
        • MaineHealth Urology - South Portland
    • Michigan
      • Ann Arbor, Michigan, Vereinigte Staaten, 48106
        • Trinity Health Saint Joseph Mercy Hospital Ann Arbor
      • Brighton, Michigan, Vereinigte Staaten, 48114
        • Trinity Health Medical Center - Brighton
      • Canton, Michigan, Vereinigte Staaten, 48188
        • Trinity Health Medical Center - Canton
      • Chelsea, Michigan, Vereinigte Staaten, 48118
        • Chelsea Hospital
      • Grand Rapids, Michigan, Vereinigte Staaten, 49503
        • Corewell Health Grand Rapids Hospitals - Butterworth Hospital
      • Iron Mountain, Michigan, Vereinigte Staaten, 49801
        • Dickinson County Healthcare System
      • Livonia, Michigan, Vereinigte Staaten, 48154
        • Trinity Health Saint Mary Mercy Livonia Hospital
      • Pontiac, Michigan, Vereinigte Staaten, 48341
        • Trinity Health Saint Joseph Mercy Oakland Hospital
    • Missouri
      • Ballwin, Missouri, Vereinigte Staaten, 63011
        • Mercy Oncology and Hematology - Clayton-Clarkson
      • Joplin, Missouri, Vereinigte Staaten, 64804
        • Freeman Health System
      • Joplin, Missouri, Vereinigte Staaten, 64804
        • Mercy Hospital Joplin
      • Rolla, Missouri, Vereinigte Staaten, 65401
        • Mercy Clinic-Rolla-Cancer and Hematology
      • Rolla, Missouri, Vereinigte Staaten, 65401
        • Phelps Health Delbert Day Cancer Institute
      • Saint Joseph, Missouri, Vereinigte Staaten, 64506
        • Heartland Regional Medical Center
      • Springfield, Missouri, Vereinigte Staaten, 65807
        • CoxHealth South Hospital
      • Springfield, Missouri, Vereinigte Staaten, 65804
        • Mercy Hospital Springfield
      • St Louis, Missouri, Vereinigte Staaten, 63131
        • Missouri Baptist Medical Center
      • St Louis, Missouri, Vereinigte Staaten, 63109
        • Mercy Infusion Center - Chippewa
      • St Louis, Missouri, Vereinigte Staaten, 63141
        • Mercy Hospital Saint Louis
      • St Louis, Missouri, Vereinigte Staaten, 63128
        • Mercy Hospital South
      • Washington, Missouri, Vereinigte Staaten, 63090
        • Mercy Hospital Washington
    • Montana
      • Billings, Montana, Vereinigte Staaten, 59102
        • Saint Vincent Frontier Cancer Center
      • Butte, Montana, Vereinigte Staaten, 59701
        • Saint James Community Hospital and Cancer Treatment Center
    • Nebraska
      • Grand Island, Nebraska, Vereinigte Staaten, 68803
        • Nebraska Cancer Specialists/Oncology Hematology West PC
    • Nevada
      • Carson City, Nevada, Vereinigte Staaten, 89703
        • Carson Tahoe Regional Medical Center
      • Las Vegas, Nevada, Vereinigte Staaten, 89102
        • OptumCare Cancer Care at Charleston
      • Las Vegas, Nevada, Vereinigte Staaten, 89135
        • Alliance for Childhood Diseases/Cure 4 the Kids Foundation
      • Las Vegas, Nevada, Vereinigte Staaten, 89144
        • Comprehensive Cancer Centers of Nevada - Town Center
      • Las Vegas, Nevada, Vereinigte Staaten, 89148
        • Comprehensive Cancer Centers of Nevada
      • Las Vegas, Nevada, Vereinigte Staaten, 89169
        • Comprehensive Cancer Centers of Nevada - Central Valley
      • Las Vegas, Nevada, Vereinigte Staaten, 89103
        • Hope Cancer Care of Nevada
      • Las Vegas, Nevada, Vereinigte Staaten, 89183
        • OptumCare Cancer Care at Fort Apache
    • New Hampshire
      • Nashua, New Hampshire, Vereinigte Staaten, 03060
        • Saint Joseph Hospital
    • New Jersey
      • Morristown, New Jersey, Vereinigte Staaten, 07960
        • Morristown Medical Center
      • Newton, New Jersey, Vereinigte Staaten, 07860
        • Newton Medical Center
      • Pompton, New Jersey, Vereinigte Staaten, 07444
        • Chilton Medical Center
      • Summit, New Jersey, Vereinigte Staaten, 07902
        • Overlook Hospital
    • New York
      • New York, New York, Vereinigte Staaten, 10032
        • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
      • The Bronx, New York, Vereinigte Staaten, 10461
        • Montefiore Medical Center-Einstein Campus
      • The Bronx, New York, Vereinigte Staaten, 10467
        • Children's Hospital at Montefiore
      • The Bronx, New York, Vereinigte Staaten, 10467
        • Montefiore Medical Center - Moses Campus
      • The Bronx, New York, Vereinigte Staaten, 10461
        • Montefiore Medical Center-Weiler Hospital
    • North Carolina
      • Charlotte, North Carolina, Vereinigte Staaten, 28204
        • Novant Health Presbyterian Medical Center
      • Greenville, North Carolina, Vereinigte Staaten, 27834
        • East Carolina University
      • Greenville, North Carolina, Vereinigte Staaten, 27834
        • ECU Health Medical Center
      • Kernersville, North Carolina, Vereinigte Staaten, 27284
        • Novant Health Cancer Institute - Kernersville
      • Kinston, North Carolina, Vereinigte Staaten, 28501
        • ECU Health Oncology Kinston
      • Mount Airy, North Carolina, Vereinigte Staaten, 27030
        • Novant Health Cancer Institute - Mount Airy
      • Pinehurst, North Carolina, Vereinigte Staaten, 28374
        • FirstHealth of the Carolinas-Moore Regional Hospital
      • Thomasville, North Carolina, Vereinigte Staaten, 27360
        • Novant Health Cancer Institute - Thomasville
      • Washington, North Carolina, Vereinigte Staaten, 27889
        • Marion L Shepard Cancer Center - ECU Health Beaufort Hospital
      • Winston-Salem, North Carolina, Vereinigte Staaten, 27103
        • Novant Health Forsyth Medical Center
    • Oklahoma
      • Oklahoma City, Oklahoma, Vereinigte Staaten, 73120
        • Mercy Hospital Oklahoma City
    • Rhode Island
      • Providence, Rhode Island, Vereinigte Staaten, 02908
        • Roger Williams Medical Center
    • South Carolina
      • Columbia, South Carolina, Vereinigte Staaten, 29203
        • Prisma Health Richland Hospital
      • Columbia, South Carolina, Vereinigte Staaten, 29220
        • Prisma Health Baptist Hospital
      • Gaffney, South Carolina, Vereinigte Staaten, 29341
        • Gibbs Cancer Center-Gaffney
      • Greenville, South Carolina, Vereinigte Staaten, 29605
        • Prisma Health Greenville Memorial Hospital
      • Greer, South Carolina, Vereinigte Staaten, 29651
        • Gibbs Cancer Center-Pelham
      • Spartanburg, South Carolina, Vereinigte Staaten, 29303
        • Spartanburg Medical Center
      • Union, South Carolina, Vereinigte Staaten, 29379
        • SMC Center for Hematology Oncology Union
    • Texas
      • San Antonio, Texas, Vereinigte Staaten, 78229
        • Audie L Murphy VA Hospital
    • Virginia
      • Lynchburg, Virginia, Vereinigte Staaten, 24501
        • Centra Alan B Pearson Regional Cancer Center
      • Richmond, Virginia, Vereinigte Staaten, 23235
        • VCU Massey Cancer Center at Stony Point
      • Richmond, Virginia, Vereinigte Staaten, 23298
        • VCU Massey Comprehensive Cancer Center
    • Washington
      • Renton, Washington, Vereinigte Staaten, 98055
        • Valley Medical Center
      • Yakima, Washington, Vereinigte Staaten, 98902
        • North Star Lodge Cancer Center at Yakima Valley Memorial Hospital
    • West Virginia
      • Huntington, West Virginia, Vereinigte Staaten, 25701
        • Edwards Comprehensive Cancer Center
      • Morgantown, West Virginia, Vereinigte Staaten, 26505
        • Monongalia Hospital
    • Wisconsin
      • Eau Claire, Wisconsin, Vereinigte Staaten, 54701
        • Marshfield Medical Center-EC Cancer Center
      • Marshfield, Wisconsin, Vereinigte Staaten, 54449
        • Marshfield Medical Center-Marshfield
      • Milwaukee, Wisconsin, Vereinigte Staaten, 53215
        • Aurora Saint Luke's Medical Center
      • Minocqua, Wisconsin, Vereinigte Staaten, 54548
        • Marshfield Medical Center - Minocqua
      • Rice Lake, Wisconsin, Vereinigte Staaten, 54868
        • Marshfield Medical Center-Rice Lake
      • Stevens Point, Wisconsin, Vereinigte Staaten, 54482
        • Marshfield Medical Center-River Region at Stevens Point
      • Weston, Wisconsin, Vereinigte Staaten, 54476
        • Marshfield Medical Center - Weston
      • Wisconsin Rapids, Wisconsin, Vereinigte Staaten, 54494
        • Marshfield Clinic - Wisconsin Rapids Center

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

13 Jahre und älter (Kind, Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Probenahmeverfahren

Nicht-Wahrscheinlichkeitsprobe

Studienpopulation

Patients undergoing treatment for cancer types with commercially available therapies.

Beschreibung

Inclusion Criteria:

  • Is consistent with OR has been diagnosed with one of the following:

    • Colorectal cancer: stage IV

    • Non-small cell or small cell lung cancer: stage III/IV

    • Prostate cancer: metastatic prostate cancer

    • Gastric cancer, not otherwise specified (NOS): stage IV

    • Esophageal cancer, NOS: stage IV

    • Adenocarcinoma of gastroesophageal junction: stage IV

    • High grade serous ovarian cancer: stage III/IV

    • Invasive breast carcinoma: stage III/IV

    • Melanoma: stage III/IV

    • Acute myeloid leukemia

    • Multiple myeloma

      • For the purposes of this study,

        • Re-staging is allowed
        • Having more than one primary cancer is allowed, if the patient is being treated solely for one of the eligible cancers listed above
  • Patient should fit in one of the following four clinical scenarios (a-d)

    • Undergoing diagnostic workup for one of the diseases listed for which treatment will likely include a new regimen of standard of care therapy OR
    • Scheduled to begin treatment with a new regimen of standard of care therapy OR
    • Currently progressing on a regimen of standard of care therapy OR
    • Currently being treated with a regimen standard of care therapy, without evidence of progression
  • Requirements for fresh tissue biospecimen collections at enrollment:

    • For clinical scenarios a, b, and c above, freshly collected tumor tissue or bone marrow (BM) aspirate must be submitted at enrollment

      • For clinical scenarios a and b, the fresh tissue collection must be prior to starting therapy

      • For clinical scenario a, the biospecimen collection must be part of a standard of care medical procedure

      • For clinical scenarios b or c, the biospecimen collection may be part of a standard of care medical procedure OR

      • The biospecimen collection may be part of a study-specific procedure ("research only biopsy"), when the patient has a tumor amenable to image guided or direct vision biopsy and is willing and able to undergo a tumor biopsy for molecular profiling

        • Note: For research-only biopsies, the biopsy must not be associated with a significant risk of severe or major complications or death; the procedure cannot be a mediastinal, laparoscopic, open or endoscopic biopsy; nor can the procedure be a brain biopsy; nor can the patient be under the age of majority as determined by each U.S. state
  • Requirements for archival tissue:

    • For clinical scenarios a and b above, archival tissue as outlined below must be submitted IF AVAILABLE

    • For clinical scenarios c and d above, archival tissue as outlined below is REQUIRED

    • Pre-existing archival material (formalin-fixed, paraffin-embedded [FFPE] block, BM aspirate, or unstained slides) that:

      • Contains the cancer type for which the participant is enrolled, and
      • Was collected no more than 5 years prior to initiation of therapy, and
      • Contains at least a surface area of 5 mm^2 and optimal surface area of 25 mm^2 or 3-5 mL cryopreserved bone marrow aspirate to yield 200 million bone marrow mononuclear cells, and
      • Contains at least 10% tumor content. 70% tumor content is optimal, and
      • No more than 1 line of standard of care systemic therapy was administered from the date of archival material collection to the date of initiation of therapy
  • Requirements for blood collection: ALL scenarios require fresh blood collection at enrollment

    • Blood collection for clinical scenarios a, b, and c must take place within 1 week of fresh tumor specimen collection
    • Blood collection for clinical scenario d must take place within 4 weeks of enrollment, and while patient is on treatment
  • Age 13 or older

  • Any sex

  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2

  • Ability to understand and willingness to sign an informed consent document. Consent may be provided by a Legally Authorized Representative (LAR) in accordance with 45 CFR 46.102(i)

  • NCI PDMR INCLUSION CRITERIA: Patients with CRC with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) status

  • NCI PDMR INCLUSION CRITERIA: Patients with CRC who are 40 years old or younger at time of collection irrespective of mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) status

  • NCI PDMR INCLUSION CRITERIA: Patients with BRCA that are either

    • Any race/ethnicity with hormone receptor positive (ER+PR+, ER+PR-, or ER-PR+)
    • African American with triple negative (ER-PR-HER2-)
  • NCI PDMR INCLUSION CRITERIA: Patients with lung cancer (LCA), prostate cancer (PCA), gastroesophageal cancer (GEC), ovarian cancer (OV), acute myeloid leukemia (AML), multiple myeloma (MML)

Exclusion Criteria:

  • Treated with or has already begun treatment with a non-standard of care therapeutic agent (investigational) in an interventional clinical trial

    • For the purposes of this study, past enrollment in clinical trials whereby the patient was randomized and treated with standard-of-care anti-cancer treatment (chemotherapy regimen, surgery and radiation therapy) is allowed
  • Uncontrolled intercurrent illness that in the physician's assessment would pose undue risk for biopsy

  • Use of full dose coumarin-derivative anticoagulants such as warfarin are prohibited. Patients may be switched to low molecular weight (LMW) heparin at physician discretion

    • Low molecular weight (LMW) heparin is permitted for prophylactic or therapeutic use

    • Factor X inhibitors are permitted

    • Use of anti-platelet drugs are permitted

      • Stopping the anticoagulation treatment for biopsy, bone marrow aspirate, or resection should be per site standard operating procedure (SOP)
  • NCI PDMR EXCLUSION CRITERIA: Patients with complete response

  • NCI PDMR EXCLUSION CRITERIA: Patients with invasive fungal infections

  • NCI PDMR EXCLUSION CRITERIA: Patients with active and/or uncontrolled infections or who are still recovering from an infection

    • Actively febrile patients with uncertain etiology of febrile episode
    • All antibiotics for non-prophylactic treatment of infection should be completed at least 1 week (7 days) prior to collection
    • No recurrence of fever or other symptoms related to infection for at least 1 week (7 days) following completion of antibiotics
  • NCI PDMR EXCLUSION CRITERIA: Patients with human immunodeficiency virus (HIV), active or chronic hepatitis (i.e. quantifiable hepatitis B virus [HBV]-deoxyribonucleic acid [DNA] and/or positive hepatitis B surface antigen [HbsAg], quantifiable hepatitis C virus [HCV]-ribonucleic acid [RNA]) or known history of HBV/HCV without documented resolution

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Beobachtungsmodelle: COHORT
  • Zeitperspektiven: PROSPECTIVE

Kohorten und Interventionen

Gruppe / Kohorte
Intervention / Behandlung
Observational (biospecimen collection, chart review)

Patients undergo collection of tissue samples during baseline and at time of disease progression and collection of blood samples throughout the study, including at time of disease progression. Patients with hematological malignancies also undergo collection of bone marrow and cerebral spinal fluid at the same time points. Archival blood and tissue, as well as bone marrow of patients with hematological malignancies, is also collected if available. Additionally, patients may undergo CT, PET/CT and/or MRI throughout the study, and may undergo paracentesis on study. Patient medical records are reviewed, and data is collected for at least 5 years.

Undergo CT

Andere Namen:
  • CT
  • KATZE
  • Computertomographie
  • Computergestützte axiale Tomographie
  • CT-Scan
  • Tomographie
  • Computerisierte Axialtomographie (Verfahren)
  • Computertomographie (CT)-Scan
  • Diagnosekatze Scan
  • Diagnose -Katzen -Scan -Service -Typ

Undergo MRI

Andere Namen:
  • MRT
  • Magnetresonanz
  • Magnetresonanztomographie-Scan
  • Medizinische Bildgebung, Magnetresonanz / Kernspinresonanz
  • HERR
  • MR-Bildgebung
  • MRT-Untersuchung
  • NMR-Bildgebung
  • NMRI
  • Kernspinresonanztomographie
  • Magnetresonanztomographie (MRT)
  • sMRT
  • Magnetresonanztomographie (Verfahren)
  • MRTs
  • Strukturelle MRT

Undergo PET/CT

Andere Namen:
  • Medizinische Bildgebung, Positronen-Emissions-Tomographie
  • HAUSTIER
  • PET-Scan
  • Positronen-Emissions-Tomographie-Scan
  • Positronen-Emissions-Tomographie
  • Pt
  • Positronen-Emissions-Tomographie (Verfahren)

Undergo collection of blood, tissue, bone marrow, and cerebral spinal fluid samples

Andere Namen:
  • Biologische Probensammlung
  • Bioprobe gesammelt
  • Probenentnahme
  • Beispielsammlung

Medical charts are reviewed and data is collected

Andere Namen:
  • Diagrammüberprüfung

Undergo paracentesis

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Procure, store and distribute longitudinal biospecimens and associated clinical data
Zeitfenster: Up to 10 years

Will procure, store and distribute longitudinal biospecimens and associated clinical data for current and future cancer research in order to elucidate molecular mechanisms of sensitivity and intrinsic or acquired resistance to standard of care systemic therapies, including immunotherapy. Cases will be grouped according to patient demographics, cancer type and treatment regimen. Statistical analysis will be descriptive and will be analyzed for each Biospecimen Source Site (BSS) as well as study aggregate.

Up to 10 years
Percentage of enrolled patients by cancer type and treatment regimen overall
Zeitfenster: Until completion of biospecimen collection, up to 3 years

Will assess the percentage of enrolled patients by cancer type and treatment regimen overall and those who contribute samples to the Drug Resistance and Sensitivity Network and other approved investigators. Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate.

Until completion of biospecimen collection, up to 3 years
Percentage of minority and underserved study participants accrued
Zeitfenster: Until completion of biospecimen collection, up to 3 years

Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate.

Until completion of biospecimen collection, up to 3 years

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Percentage of minority and underserved study participants accrued
Zeitfenster: Until completion of biospecimen collection, up to 3 years

Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate.

Until completion of biospecimen collection, up to 3 years
Pan-cancer gene panel tumor next generation sequencing test
Zeitfenster: Until completion of biospecimen collection, up to 3 years

Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate.

Until completion of biospecimen collection, up to 3 years
Cancer Research Data Commons, The Cancer Imaging Archive and database of Genotypes and Phenotypes data contribution
Zeitfenster: Until completion of biospecimen collection, up to 3 years

Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate.

Until completion of biospecimen collection, up to 3 years
Percentage of enrolled patients for whom molecular profiling is attempted
Zeitfenster: Until completion of biospecimen collection, up to 3 years

Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. Will also be assessed by patient demographics, cancer type and treatment regimen.

Until completion of biospecimen collection, up to 3 years
Percentage of enrolled patients for whom molecular profiling results are generated
Zeitfenster: Until completion of biospecimen collection, up to 3 years

Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. Will also be assessed by patient demographics, cancer type and treatment regimen.

Until completion of biospecimen collection, up to 3 years
Percentage of enrolled patients for whom samples are obtained at each longitudinal timepoint
Zeitfenster: Until completion of biospecimen collection, up to 3 years

Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. Will also be assessed by patient demographics, cancer type and treatment regimen.

Until completion of biospecimen collection, up to 3 years
Percentage of collected biospecimens that are delivered to the Patient Derived Models Repository
Zeitfenster: Until completion of biospecimen collection, up to 3 years

Statistical analysis will be descriptive and will be analyzed for each BSS as well as study aggregate. Will also be assessed by patient demographics, cancer type and treatment regimen.

Until completion of biospecimen collection, up to 3 years

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Hauptermittler: Lyndsay N Harris, National Cancer Institute (NCI)

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

11. November 2020

Primärer Abschluss (Geschätzt)

30. April 2027

Studienabschluss (Geschätzt)

30. April 2027

Studienanmeldedaten

Zuerst eingereicht

18. März 2020

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

18. März 2020

Zuerst gepostet (Tatsächlich)

19. März 2020

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

12. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

11. November 2026

Zuletzt verifiziert

1. Oktober 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • NCI-2020-00750
  • NCI-2020-00750 (Registrierungskennung: CTRP (Clinical Trial Reporting Program))
  • 10323 (Andere Kennung: CTEP)
  • 10323 (Andere Kennung: Division of Cancer Treatment and Diagnosis)

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .